Adding abemaciclib to standard endocrine therapy reduces the risk of death and recurrence in patients with breast cancer.

Compugen’s Unigen AI/ML platform drives the discovery of potentially novel checkpoints. Find out what nudges me to rate CGEN ...

Market Size was valued at around US $11.9 billion in 2024, the market is projected to surge past US $30.4 billion by 2033, ...

Although several novel agents are on the horizon, including next-generation tyrosine kinase inhibitors for tertiary mutations ...

(A) The Incucyte® Apoptosis Assay allows automated imaging and quantitative analysis of every well of a 96/384-well plate, ...

A new preliminary study published in Nature suggests that COVID-19 vaccines might actually boost the immune system to make ...

Nuvectis Pharma, Inc. (NASDAQ: NVCT), a clinical stage biopharmaceutical company focused on the development of innovative ...

Medicine regulatory agencies in many countries don’t have the capacity to measure the quality of anticancer drugs.

The number of people receiving treatment for cancer has risen dramatically in the last decade in many African countries. For ...

OncoC4 announced today that China's National Medical Product Administration (NMPA) has granted Breakthrough Therapy Designation (BTD) for gotistobart (BNT316/ONC392) for the treatment of patients with ...

MAIA also announced that it has enrolled five patients from Taiwan and Turkey in the expansion phase of its THIO-101 Phase 2 trial. Screening for the trial is ongoing in Europe and Asia. With ...

Among them, Lucentis® is the first anti-vascular endothelial growth factor (VEGF) drug approved for ophthalmic use in China, and has accumulated mature clinical application experience, providing ...